Results of a phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response pathway deficient neoplasms. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback